In people living with obesity and T2D, plasma levels of intact GIP after breakfast, lunch and dinner are, as expected, increased in individuals receiving DPP4 inhibitors (saxagliptin, sitagliptin or vildagliptin) relative to those receiving placebo, but this does not reflect increased secretion [505]. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.